Meissa Vaccines Inc

Founded in 1997, ChemoCentryx is a clinical-based pharmaceutical company that discovers and develops orally-administered small molecule therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has developed EnabaLink, which is a drug recovery technology that is designed to accelerate productive drug recovery program. The company also conducts preclinical evaluation of a series of anticancer compounds that target the CXCR7 chemokine receptor. ChemoCentryx evaluates a series of compounds that target the C5a chemo-attractant receptor to treat age-related macular degeneration, rheumatoid arthritis and systemic lupus erythematosus and other disorders. It has entered into a strategic alliance with Glaxo Group, which is an affiliate of GlaxoSmithKline. ChemoCentryx maintains its headquarters in Mountain View, Calif.

Phoenix Pharmaceuticals, founded in 1994 by industry pioneers, is a leading producer of over 7,000 peptide-related products. Specializing in the fields of obesity, cardiovascular, and diabetes, the company offers a wide range of innovative solutions for these health concerns. With a strong focus on research and development, Phoenix Pharmaceuticals delivers high-quality products and services to meet the needs of the medical and scientific communities. Stay updated on the latest news and offerings through their comprehensive catalogs and online resources. Generated from their available business information

Alumis provides precision medicines. They transform the lives of patients with autoimmune diseases. They bring a proven track record in precision drug development of groundbreaking therapies. They rewrite the autoimmune treatment playbook with a unique precision analytics platform to advancing their understanding of immunologic diseases. They build a pipeline of therapeutics based on genetically validated targets for application in the treatment of multiple autoimmune disease indications.